SPRC - EXCLUSIVE: Clearmind Medicine's Psychedelic-Based Treatment Shows Encouraging Preclinical Activity In Obesity Metabolic Disorders | Benzinga
Clearmind Medicine Inc (NASDAQ: CMND) has released results from its pre-clinical trial of the combination therapy.
The treatment includes Clearmind's MEAI, a proprietary psychedelic treatment for various addictions, obesity and metabolic disorders, and depression, and SciSparc Ltd's (NASDAQ: SPRC) Palmitoylethanolamide (PEA), an anti-inflammatory agent and the active ingredient of its proprietary CannAmide.
The trial aimed to identify the optimal dosage for their combination to observe their safety and impact on various metabolic and ...